• Japanese
  • Korean
  • Chinese
Cover Image

Antifungal Drugs: Technologies and Global Markets

The global market for human antifungal therapeutics reached nearly $11.6 billion in 2012 and $11.8 billion in 2013. This market is expected to grow to nearly $13.9 billion in 2018 with a compound annual growth rate (CAGR) of 3.2% over the five-year period from 2013 to 2018.

This report provides:

  • An overview of the global market for human antifungal therapeutics
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
  • Identification of new antifungal research, development, and drug applications
  • Information on over the counter (OTC) vs. prescription products
  • Comprehensive profiles of leading companies in the industry.

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The goal of BCC Research in conducting this study was to determine the current status of the global human antifungal market and assess its growth potential over the five-year period from 2013 to 2018. This report covers approved human therapeutics, with a heavy focus on therapeutics in early development. These new molecular and biological entities are from traditional pharmaceutical sources, naturally derived synthetic chemicals and biological sources as well as the "herbal natural folk medicine" marketplace. If an approved or well-known medicine is being studied in combination with another molecular entity, it is considered a new therapy and often has been included for review. New drug and patent applications are presented as the study focuses on new methods of drug administration, drug clinical trials, and discovery and development.

It should be noted that there is a strong emphasis on early research due to the critical need for new and more effective medicines; hence, BCC Research is including a section of medicines intended for human utilization that are in clinical testing as well as information on new and novel in vitro therapies. Greater than 98% of medicines at the preclinical level are terminated prior to their utilization in humans, and the research in this area is vast. We are limiting this research to therapies that depict a positive result or that represent a very rare and novel approach worthy of further review from R&D groups.

Our key objective in this report is to present an in-depth analysis of the current human antifungal market and to explore its future direction. In the last five years there has been a decrease in the number of patent applications filed in this area. Between 1990 and 1999 there were six U.S. patents granted-evidence of the evolution of drug resistance and an increasing mortality rate.[1],[2]

REASONS FOR DOING THIS STUDY

Fungi are highly resistant microbiological eukaryotic microorganisms. In other words, they are becoming drug-resistant to the approved compounds and some therapies later in clinical development. The therapies are designed to eradicate these fungi through the various antifungal mechanisms of action, such as disrupting reproductive capabilities, destroying cell walls or modifying fungal DNA and cell functioning. It is a given fact that infestations in humans, animals, plants and the environment are on the rise, with many having lethal consequences in both the immunocompetent and the immunocompromised. That being the case, BCC Research was particularly interested in examining the antifungal market growth of developing products depicting efficacy. We are including data regarding the market shift for those products that are now relegated to over-the-counter (OTC) status that previously had only been provided by prescription; moreover, we will identify new antifungal research, development, new drug applications and novel approaches to the market.

Previously, BCC Research examined the antifungal market in its 2003 report, PHM029A The Market for Antifungal Drugs, in PHM029B Global Markets for Antifungal Agents and in PHM029C Antifungal Drugs: Technologies and Global Markets. Due to the rapidly changing market, BCC Research chose to reexamine the marketplace through another analysis and project its new growth potential. Additionally, PHM029A focused only on human fungal diseases and associated antifungals; PHM029B incorporated the marketplace for antifungals in the veterinary, agricultural and environmental industries; and PHM029C and PHM029D focused on human therapeutics with an intensive focus on human therapeutics in the developmental pipeline. PHM029E is an update of PHM029D.

INTENDED AUDIENCE

This report was prepared as a study of the global antifungal marketplace based on fungal infections and infestations with a focus on human therapeutics. Information is presented on the antifungal industry in general, specific pharmaceuticals and chemical agents, new technology within the market, new and novel drug applications and market-related issues. In many cases actual revenue is given for the period of 2012 and 2013, with projections of trends and compound annual growth rates (CAGRs) 2013 through 2018.

This study will be of significant interest to hospitals, pharmacies, pharmaceutical companies, biopharmaceutical researchers, pharmaceutical company directors and marketing executives, contract research organizations (CROs), chemists, physicians, nurses, physician assistants, product managers and representatives, and all manner of institutional directors ranging from nursing homes and schools to long-term-care facilities both public and private. It will also be of interest to biologists and those interested in the field of mycology.

SCOPE OF REPORT

This study examines human applications both currently marketed and in the development of antifungal technologies. In an extensive analysis, BCC Research examines each market segment, presents its current market status and offers various forecasts for growth over the next five years. Other factors such as Food and Drug Administration (FDA) restrictions, government legislation, fungal resistance and changes in consumerism such as a greater demand for OTC medications and/or natural and alternative remedies are also highlighted. Our financial and sales analysis focuses on the available figures from 2012 to 2013, with estimates for 2018, including CAGR as a percentage.

METHODOLOGY

Through an extensive industry survey inclusive of online database searches of industry-specific data sources coupled with financial, trade, government and marketing database sources as well as interviews via correspondence or telephone with independent sources comprising companies, government agencies and academic experts, BCC Research was able to compile data to present our analysis of the antifungal market by market segment.

INFORMATION SOURCES

Of the companies and agencies surveyed, the majority were pharmaceutical or compound manufacturers. Additional information was supplied by known industry or trade sources.

ANALYST CREDENTIALS

Mary Anne Crandall is an expert industry analyst specializing in the pharmaceutical industry for over 22 years. She has completed several in-depth studies on various medical topics requiring both medical expertise and excellent knowledge of the pharmaceutical industry. Ms. Crandall has extensive knowledge in the medical field, has an M.S. in psychology and is currently working on her Ph.D.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • INTENDED AUDIENCE
  • SCOPE OF REPORT
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • SUMMARY TABLE GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL THERAPEUTICS, BY GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL THERAPEUTICS, BY GEOGRAPHIC REGION, 2012-2018 ($ MILLIONS)

CHAPTER 3 OVERVIEW

  • HISTORY AND CURRENT STATE OF ANTIFUNGALS
  • TYPES OF PATHOGENIC FUNGI
  • DEFINITION OF THE INDUSTRY
  • CONCEPTS IN THE INDUSTRY
  • IMPORTANCE OF THE INDUSTRY
  • PRODUCT LIFE CYCLES
  • TABLE 1 DRUG DEVELOPMENT LIFECYCLE FOLLOWING DISCOVERY OF NEW DRUG
  • DEVELOPMENT OF ANTIFUNGALS
  • FDA-APPROVED ANTIFUNGALS
    • AZOLE ANTIFUNGALS
    • ECHINOCANDINS
    • POLYENES
    • ALLYLAMINES
    • MISCELLANEOUS ANTIFUNGALS
  • FUTURE DEVELOPMENTS
    • HUMAN CLINICAL DEVELOPMENT, 2011 TO 2013
    • NEW DRUG ACTIVITY
    • TABLE 2 CLINICAL TRIALS OF ALL ANTIFUNGAL DRUG THERAPIES AND COMBINATIONS BY ALL DATE FIELDS, 2011-2013 (NUMBER)
    • TABLE 3 SELECTED GLOBAL CLINICAL TRIALS OF ALL ANTIFUNGAL DRUG THERAPIES THAT EITHER ARE COMPLETED OR ESTIMATED TO BE COMPLETED BETWEEN 2009 AND 2013 (NUMBER)
  • ACTIVE OR COMPLETED STUDIES POSTED OR UPDATED, 2009 TO 2013
  • TABLE 4 SELECTED ACTIVE OR COMPLETED STUDIES, 2009 TO 2014

CHAPTER 4 INTRODUCTION TO INDUSTRY APPLICATIONS OF ANTIFUNGAL MEDICINAL THERAPEUTICS

  • SCOPE OF APPLICATIONS: HUMAN HEALTHCARE
  • HUMAN FUNGAL INFECTIONS
    • RISK FACTORS FOR DEVELOPING FUNGAL INFECTIONS
    • TABLE 5 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS
    • FUNGAL SPECIES THAT CAUSE INFECTION IN HUMANS
      • Candidiasis
        • Some Basic Facts about Candida Infections
        • Cutaneous Candidiasis
        • Chronic Mucocutaneous Candidiasis
        • GI Tract Candidiasis
        • Respiratory Tract Candidiasis
        • Genitourinary Tract Candidiasis
        • Hepatosplenic Candidiasis
        • Systemic Candidiasis
        • Candidemia
        • Disseminated Candidiasis
      • Aspergillosis
      • Blastomycosis
      • Coccidioidomycosis
      • Cryptococcosis
      • Dermatophytosis
      • Histoplasmosis
      • Onychomycosis
      • Paracoccidioidomycosis
      • Pseudallescheriasis
      • Sporotrichosis
      • Zygomycosis
      • TABLE 6 INCIDENCE OF COMMON FUNGAL DISEASES
    • MORE RARE FUNGAL INFECTIONS AND DISORDERS
      • Literature Review
  • FUNGAL DRUG RESISTANCE
    • CURRENT DRUG RESISTANCE TOPICS: A GLOBAL VIEW
    • MDR SPECIES
      • Literature Review
      • TABLE 7 COMMON REASONS FOR FUNGAL RESISTANCE
    • STRATEGIES TO IMPROVE RESPONSE AND DECREASE MORTALITY
      • Literature Review

CHAPTER 5 HUMAN ANTIFUNGAL AGENTS

  • TABLE 8 GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL CONSUMPTION BY PRODUCT TYPE, THROUGH 2018 ($ MILLIONS)
  • CLASSES OF ANTIFUNGALS
    • ECHINOCANDINS
      • Literature Review
    • AZOLES
      • Literature Review
    • POLYENES
      • Literature Review
    • OTHER
      • TABLE 9 GLOBAL PRESCRIPTION ANTIFUNGAL PHARMACEUTICAL SALES - TRIAZOLES AND ECHINOCANDINS VERSUS OTHER ANTIFUNGALS, THROUGH 2018 ($ MILLIONS)
      • TABLE 10 PHARMACEUTICAL ANTIFUNGALS BY CLASS/MECHANISM OF ACTION (%)
      • FIGURE 1 PERCENTAGE OF RECOGNIZED ANTIFUNGAL DRUGS (%)
      • TABLE 11 MAJOR ANTIFUNGAL AGENTS BY CLASS AND AVERAGE SALES PRICE PER DOSAGE, 2013
      • TABLE 12 FUNGAL INFECTION AND TRADITIONAL PHARMACEUTICAL REMEDY
      • TABLE 13 TYPES OF CANDIDAL INFECTION AND PHARMACEUTICAL TREATMENT
  • SIDE EFFECTS
  • TABLE 14 LIFE-THREATENING SIDE EFFECTS FROM ANTIFUNGAL PHARMACEUTICALS
  • OTC ANTIFUNGAL PREPARATIONS
  • TABLE 15 COMMON FUNGAL INFECTIONS AND OTC ROUTES OF ADMINISTRATION
  • NATURAL ANTIFUNGAL REMEDIES
    • TYPES OF NATURAL ANTIFUNGAL REMEDIES
      • Herbal Remedies
      • Enzyme-Based Antifungal Agents
      • TABLE 16 COMMON NATURAL ANTIFUNGALS
    • SUMMARY OF SELECTED NATURAL ANTIFUNGALS
      • Aloe
        • Literature Review
      • Curcumin
        • Literature Review
      • Mint
        • Literature Review
      • Wild Marjoram
        • Literature Review
      • Radish
        • Literature Review
      • Parnafungins
        • Literature Review
      • Ginseng
        • Literature Review
      • Walnut
        • Literature Review
      • Pau d'arco
        • Literature Review
      • Garlic
        • Literature Review
      • Grapefruit Seed
        • Literature Review
      • Olive Leaf
        • Literature Review
      • Goldenseal
        • Literature Review
      • Oregano
        • Literature Review
      • Tea Tree
        • Literature Review
    • NATURAL REMEDIES IN EARLIER DEVELOPMENT
      • Literature Review
      • TABLE 17 GLOBAL MARKET FORECAST FOR HUMAN OTC AND ALTERNATIVE ANTIFUNGAL CONSUMPTION BY PRODUCT TYPE, THROUGH 2018 ($ MILLIONS)
    • LABORATORY TESTING AND HISTOPATHOLOGY FOR FUNGAL INFECTIONS IN HUMANS
      • Specimen Examination
      • Cultures
      • Blood Serology
    • OTC/ALTERNATIVE HEALTHCARE APPROACHES TO TESTING AND DIAGNOSIS OF FUNGAL INFECTIONS
      • CAM Testing and Specialized Laboratories
      • Questionnaire for Symptoms
      • New Developments

CHAPTER 6 COMMON ENVIRONMENTAL FUNGI

  • MOLDS AND THE HUMAN ISSUES THEY PRODUCE
  • WHY ENVIRONMENTAL MOLD IS A UNIQUE PROBLEM
  • HEALTH RISKS DUE TO ENVIRONMENTAL FUNGI AND MOLD
  • TABLE 18 COMMON HEALTH SYMPTOMS BASED ON ENVIRONMENTAL FUNGI AND MOLDS
  • TABLE 19 RISK FACTORS ASSOCIATION WITH ENVIRONMENTAL MOLD REACTIONS
  • TABLE 20 COMMON SOURCE LOCATIONS FOR ENVIRONMENTAL MOLDS
  • ENVIRONMENTAL MOLDS
    • ALTERNARIA
      • Literature Review
    • ASPERGILLUS
      • Literature Review
    • CLADOSPORIUM
      • Literature Review
    • PENICILLIUM
      • Literature Review
    • EUROTIUM
      • Literature Review
    • RHIZOPUS
      • Literature Review
    • MUCOR
      • Literature Review
    • GEOTRICHUM
      • Literature Review
    • FUSARIUM
      • Literature Review
    • STACHYBOTRYS
      • Literature Review
    • WALLEMIA
      • Literature Review
    • TRICHOTHECIUM
      • Literature Review
    • SCOPULARIOPSIS BREVICAULIS
      • Literature Review
    • SCYTALIDIUM DIMIDIATUM
      • Literature Review
    • TRICHODERMA
      • Literature Review
    • PAECILOMYCES VARIOTII
      • Literature Review

CHAPTER 7 GOVERNMENT REGULATORY AGENCIES AND PROFESSIONAL ASSOCIATIONS

  • GOVERNMENT REGULATIONS
    • FDA
    • TABLE 21 SELECTED ANTIFUNGAL WARNING LETTERS FOR THE HUMAN SEGMENT FROM THE FDA TO MANUFACTURERS, 1997-2014
    • EPA
    • USDA
    • FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS
  • PROFESSIONAL ASSOCIATIONS
    • MEDICAL AND VETERINARY ASSOCIATIONS
    • AGRICULTURAL ASSOCIATIONS
    • OTHER ENVIRONMENTAL ASSOCIATIONS

CHAPTER 8 ANTIFUNGAL COMPANIES

  • HUMAN HEALTHCARE
  • MANUFACTURERS OF PRESCRIPTION PHARMACEUTICALS
  • TABLE 22 MAJOR GLOBAL MANUFACTURERS OF ANTIFUNGAL PHARMACEUTICALS FOR HUMAN CONSUMPTION
  • FIGURE 2 GLOBAL ANTIFUNGAL PHARMACEUTICAL MANUFACTURERS BY COUNTRY (%)
    • MAJOR PHARMACEUTICAL MANUFACTURER PROFILES
    • TABLE 23 COMPETITIVE MARKET SHARE BY PERCENT, 2013 (%)
    • FIGURE 3 COMPETITIVE MARKET SHARE BY PERCENT, 2013 (%)
      • Astellas Pharma Inc.
      • Bayer HealthCare
      • Enzon Pharmaceuticals
      • Galderma Pharma SA/Galderma SA
      • Gilead Sciences Inc.
      • Novartis International AG
      • Pfizer Inc.
      • Taro Pharmaceutical Industries, Ltd.
      • Taro USA Inc.
      • Teva Pharmaceutical Industries, Ltd.
      • Valeant Pharmaceuticals
  • OTC ANTIFUNGAL MANUFACTURERS
    • PHARMACEUTICAL OTC MARKET 12
    • TABLE 24 MAJOR HUMAN OTC ANTIFUNGAL MANUFACTURERS AND PRODUCTS
    • MAJOR PHARMACEUTICAL-BASED OTC MANUFACTURER PROFILES
      • Alva-Amco Pharmacal
      • Blaine Labs
      • Dartmouth Pharmaceuticals
      • Kramer Consumer Healthcare
      • Novartis International AG
      • McNeil Consumer Healthcare
      • PEDiNOL Pharmacal, Inc.
      • Perrigo Company plc
      • Stiefel Laboratories, Inc
      • Tarmac Products
    • ALTERNATIVE OTC MANUFACTURERS
    • TABLE 25 COMMONLY AVAILABLE ALTERNATIVE ANTIFUNGALS
    • MAJOR ALTERNATIVE OTC MANUFACTURER PROFILES
      • Crystal Star Herbal Nutrition
      • Enzymedica 17
      • Forest Herbs Research Ltd.
      • Garden of Life
      • King Bio
      • Life Entension Nutrition Center
      • Michael's Naturopathic Programs
      • Nature's Plus
      • NOW Foods
      • Nutrition Now
      • PROSymbiotics
      • Pure Essence Laboratories
      • Rainbow Light
      • Renew Life
      • Solaray
      • Vitanica

CHAPTER 9 ANTIFUNGAL INDUSTRY

  • ANTIFUNGAL MARKET TRENDS: HUMAN HEALTHCARE
    • ACCELERATING ANTIFUNGAL DRUG DEVELOPMENT
    • TABLE 26 NEW PRESCRIPTION ANTIFUNGALS, 2005 TO MARCH 2014
    • INCREASED TYPES OF TESTING
      • Need to Increase Use and Acceptance of Newer Drugs
    • EXPERIMENTAL RESEARCH - CLINICAL TRIALS PERFORMED AND SELECTED PRECLINICAL AND IN VIVO STUDIES
    • A GENERAL OVERVIEW OF NONPHARMACEUTICAL ANTIFUNGAL TECHNOLOGIES
      • Laser and Photodynamic Therapy
        • Studies
        • Literature Review
      • mAbs
      • Diagnostics and Assays
        • Literature Review
      • Computer Modeling Technology
        • Literature Review
      • R&D SECTION: AN OVERVIEW OF PRODUCTS IN DEVELOPMENT
      • TABLE 27 ANTIFUNGALS IN DEVELOPMENT
      • TRENDS IN CLASS USED AND ADMINISTRATION METHOD
      • TABLE 28 PHARMACEUTICAL ANTIFUNGALS BY ROUTE OF ADMINISTRATION 2013 (%)
      • FIGURE 4 PHARMACEUTICAL ANTIFUNGALS BY ROUTE OF ADMINISTRATION, 2013 (%)
      • TABLE 29 GLOBAL MARKET FORECAST FOR ANTIFUNGAL PRODUCTS BY ROUTE OF ADMINISTRATION, THROUGH 2018 ($ MILLIONS)
      • UTILIZATION OF OTC AND NATURAL/ALTERNATIVE ANTIFUNGAL AGENTS
        • Shifting the Market from Prescription to OTC
        • Market Demand for OTC Products

CHAPTER 10 PATENT ANALYSIS

  • PURPOSE OF A PATENT ANALYSIS
  • DUE CARE IN REVIEWING THE PATENT ANALYSIS
  • NEW ANTIFUNGAL PATENTS ISSUED
  • TABLE 30 U.S. ANTIFUNGAL PATENT TRENDS, 1990-2013
  • TABLE 31 SELECTED NEW U.S. ANTIFUNGAL PATENTS ISSUED 2007-2013
  • TABLE 32 ASSIGNEES OF TWO OR MORE U.S. PATENTS FOR ANTIFUNGAL PRODUCTS, 2007-2013
  • TABLE 33 U.S. PATENT TRENDS BY COUNTRY, 2007-2013 (NO. OF PATENTS/%)
  • FIGURE 5 U.S. PATENT TRENDS BY COUNTRY, 2007-2013 (%)
  • TRENDS IN PATENT APPLICATIONS
  • TABLE 34 U.S. PATENT APPLICATIONS BY ANTIFUNGAL MECHANISM OF ACTION, 2007-2013 (NO./%)
  • FIGURE 6 U.S. PATENT APPLICATIONS BY ANTIFUNGAL MECHANISM OF ACTION, 2007 THROUGH 2013 (%)
  • TABLE 35 NEW U.S. PATENT APPLICATIONS, 2007-2013
  • TABLE 36 RECENT TRENDS IN PATENT APPLICATIONS FOR ANTIFUNGALS BY MECHANISM OF ACTION, 2007-2013
  • TABLE 37 U.S. PATENT APPLICATION TRENDS BY COUNTRY, 2007-2013 (NO. OF PATENTS/%)
  • FIGURE 7 U.S. ANTIFUNGAL PATENT APPLICATIONS BY COUNTRY 2007-2013 (%)
  • PATENT EXPIRATIONS
  • TABLE 38 PATENT EXPIRATIONS 2006-2018

CHAPTER 11 APPENDIX

  • TABLE 39 PHARMACEUTICAL COMPANIES

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL THERAPEUTICS, BY GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 1 DRUG DEVELOPMENT LIFECYCLE FOLLOWING DISCOVERY OF NEW DRUG
  • TABLE 2 CLINICAL TRIALS OF ALL ANTIFUNGAL DRUG THERAPIES AND COMBINATIONS BY ALL DATE FIELDS, 2011-2013 (NUMBER)
  • TABLE 3 SELECTED GLOBAL CLINICAL TRIALS OF ALL ANTIFUNGAL DRUG THERAPIES THAT EITHER ARE COMPLETED OR ESTIMATED TO BE COMPLETED BETWEEN 2009 AND 2013 (NUMBER)
  • TABLE 4 SELECTED ACTIVE OR COMPLETED STUDIES, 2009 TO 2014
  • TABLE 5 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS
  • TABLE 6 INCIDENCE OF COMMON FUNGAL DISEASES
  • TABLE 7 COMMON REASONS FOR FUNGAL RESISTANCE
  • TABLE 8 GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL CONSUMPTION BY PRODUCT TYPE, THROUGH 2018 ($ MILLIONS)
  • TABLE 9 GLOBAL PRESCRIPTION ANTIFUNGAL PHARMACEUTICAL SALES - TRIAZOLES AND ECHINOCANDINS VERSUS OTHER ANTIFUNGALS, THROUGH 2018 ($ MILLIONS)
  • TABLE 10 PHARMACEUTICAL ANTIFUNGALS BY CLASS/MECHANISM OF ACTION (%)
  • TABLE 11 MAJOR ANTIFUNGAL AGENTS BY CLASS AND AVERAGE SALES PRICE PER DOSAGE, 2013
  • TABLE 12 FUNGAL INFECTION AND TRADITIONAL PHARMACEUTICAL REMEDY
  • TABLE 13 TYPES OF CANDIDAL INFECTION AND PHARMACEUTICAL TREATMENT
  • TABLE 14 LIFE-THREATENING SIDE EFFECTS FROM ANTIFUNGAL PHARMACEUTICALS
  • TABLE 15 COMMON FUNGAL INFECTIONS AND OTC ROUTES OF ADMINISTRATION
  • TABLE 16 COMMON NATURAL ANTIFUNGALS
  • TABLE 17 GLOBAL MARKET FORECAST FOR HUMAN OTC AND ALTERNATIVE ANTIFUNGAL CONSUMPTION BY PRODUCT TYPE, THROUGH 2018 ($ MILLIONS)
  • TABLE 18 COMMON HEALTH SYMPTOMS BASED ON ENVIRONMENTAL FUNGI AND MOLDS
  • TABLE 19 RISK FACTORS ASSOCIATION WITH ENVIRONMENTAL MOLD REACTIONS
  • TABLE 20 COMMON SOURCE LOCATIONS FOR ENVIRONMENTAL MOLDS
  • TABLE 21 SELECTED ANTIFUNGAL WARNING LETTERS FOR THE HUMAN SEGMENT FROM THE FDA TO MANUFACTURERS, 1997-2014
  • TABLE 22 MAJOR GLOBAL MANUFACTURERS OF ANTIFUNGAL PHARMACEUTICALS FOR HUMAN CONSUMPTION
  • TABLE 23 COMPETITIVE MARKET SHARE BY PERCENT, 2013 (%)
  • TABLE 24 MAJOR HUMAN OTC ANTIFUNGAL MANUFACTURERS AND PRODUCTS 22
  • TABLE 25 COMMONLY AVAILABLE ALTERNATIVE ANTIFUNGALS
  • TABLE 26 NEW PRESCRIPTION ANTIFUNGALS, 2005 TO MARCH 2014
  • TABLE 27 ANTIFUNGALS IN DEVELOPMENT
  • TABLE 28 PHARMACEUTICAL ANTIFUNGALS BY ROUTE OF ADMINISTRATION 2013 (%)
  • TABLE 29 GLOBAL MARKET FORECAST FOR ANTIFUNGAL PRODUCTS BY ROUTE OF ADMINISTRATION, THROUGH 2018 ($ MILLIONS)
  • TABLE 30 U.S. ANTIFUNGAL PATENT TRENDS, 1990-2013
  • TABLE 31 SELECTED NEW U.S. ANTIFUNGAL PATENTS ISSUED 2007-2013
  • TABLE 32 ASSIGNEES OF TWO OR MORE U.S. PATENTS FOR ANTIFUNGAL PRODUCTS, 2007-2013
  • TABLE 33 U.S. PATENT TRENDS BY COUNTRY, 2007-2013 (NO. OF PATENTS/%)
  • TABLE 34 U.S. PATENT APPLICATIONS BY ANTIFUNGAL MECHANISM OF ACTION, 2007-2013 (NO./%)
  • TABLE 35 NEW U.S. PATENT APPLICATIONS, 2007-2013
  • TABLE 36 RECENT TRENDS IN PATENT APPLICATIONS FOR ANTIFUNGALS BY MECHANISM OF ACTION, 2007-2013
  • TABLE 37 U.S. PATENT APPLICATION TRENDS BY COUNTRY, 2007-2013 (NO. OF PATENTS/%)
  • TABLE 38 PATENT EXPIRATIONS 2006-2018
  • TABLE 39 PHARMACEUTICAL COMPANIES

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL THERAPEUTICS, BY GEOGRAPHIC REGION, 2012-2018 ($ MILLIONS)
  • FIGURE 1 PERCENTAGE OF RECOGNIZED ANTIFUNGAL DRUGS (%)
  • FIGURE 2 GLOBAL ANTIFUNGAL PHARMACEUTICAL MANUFACTURERS BY COUNTRY (%)
  • FIGURE 3 COMPETITIVE MARKET SHARE BY PERCENT, 2013 (%)
  • FIGURE 4 PHARMACEUTICAL ANTIFUNGALS BY ROUTE OF ADMINISTRATION, 2013 (%)
  • FIGURE 5 U.S. PATENT TRENDS BY COUNTRY, 2007-2013 (%)
  • FIGURE 6 U.S. PATENT APPLICATIONS BY ANTIFUNGAL MECHANISM OF ACTION, 2007 THROUGH 2013 (%)
  • FIGURE 7 U.S. ANTIFUNGAL PATENT APPLICATIONS BY COUNTRY 2007-2013 (%)
Show More
Pricing